Diagnosis and management of marfan syndrome

Current Sports Medicine Reports

Volumn 9, Issue 2, 2010, Pages 93-98

  Iams, Helen D ^a  

^a High Performance Sports Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRILLIN 1; TRANSFORMING GROWTH FACTOR BETA;

AORTA VALVE REGURGITATION; ARTERIAL STIFFNESS; ARTERY DILATATION; AUTOSOMAL DOMINANT INHERITANCE; BLOOD PRESSURE REGULATION; CHROMOSOME 15; CLINICAL EVALUATION; CLINICAL FEATURE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DETERIORATION; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; EARLY INTERVENTION; EYE EXAMINATION; FIBER; FOLLOW UP; GENE MUTATION; GENETIC PROCEDURES; HEART SURGERY; HUMAN; JOINT STABILITY; LIFE EXPECTANCY; MAGNETIC RESONANCE ANGIOGRAPHY; MARFAN SYNDROME; MONITORING; MORBIDITY; MYOPIA; PATHOPHYSIOLOGY; PATIENT CARE; PHENOTYPE; PHYSICAL ACTIVITY; PREVALENCE; QUALITY OF LIFE; REVIEW; SCREENING; SIGNAL TRANSDUCTION; SPORTING EVENT;

ADOLESCENT; CHILD; GENETIC TESTING; HUMANS; MARFAN SYNDROME; MOTOR ACTIVITY; PHENOTYPE; UNITED STATES;

EID: 77950836381     PISSN: 1537890X     EISSN: 15378918     Source Type: Journal    
DOI: 10.1249/JSR.0b013e3181d4066c     Document Type: Review

References (44)

1. Boyer JK, Gutierrez F, Braverman AC. Approach to the dilated aortic root. Curr. Opin. Cardiol. 2004; 19:563-569
2. Braverman AC. Exercise and the Marfan syndrome. Med. Sci. Sports Exerc. 1998; 30(10 Suppl.):S387-95.
3. Cholley BP, Shroff SG, Sandelski J, et al. Aortic and other vascular disease: differential effects of chronic oral antihypertensive therapies on systemic arterial circulation and ventricular energetic in African- American patients. Circulation. 1995; 91:1052-1062
4. Collod-Beroud G, Le Bourdelles S, Ades L, et al. Update of the UMDFBN1 mutation database and creation of an FBN1 polymorphism database. Hum. Mutat. 2003; 22:199-208.
5. De Paepe A, Devereux RB, Dietz HC, Hennekam RCM, Pyeritz RE. Revised diagnostic criteria for the Marfan syndrome. Am. J. Med. Genetics. 1996; 62:417-426
6. Devereux RB, Brown WT, Kramer-Fox R, Sacks I. Inheritance of mitral valve prolapsed: effect of age and sexing gene expression. Ann. Intern. Med. 1982; 97:826-832
7. Dietz HC, Pyeritz RE. Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. Hum. Molec. Genet. 1995; 4:1799-1809
8. DiSilvestre M, Greggi T. Surgical treatment for scoliosis in Marfan syndrome. Spine. 2005; 30:E597-604.
9. Erkula G, Jones KB, Sponseller PD, Dietz HC, Pyeritz RE. Growth and maturation of Marfan syndrome. Am. J. Med. Genet. 2002; 109:100-115
10. Foran JRH, Pyeritz RE, Dietz HC III, Sponseller PD. Characterization of the symptoms associated with dural ectasia in the Marfan patient. Am. J. Med. Genet. 2005; 134:58-65.
11. Glesby MJ, Pyeritz RE. Association of mitral valve prolapsed and systemic abnormalities of connective tissue. JAMA. 1989; 262:5238.
12. Gross D, Robinson L, Smith L, et al. Severe perinatal Marfan syndrome. Pediatrics. 1989; 84:84-89
13. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006; 312:117-121
14. Hirata K, Triposkiadis F, Sparks E, et al. The Marfan syndrome: abnormal aortic elastic properties. J. Am. Coll. Cardiol. 1991; 18:57-63.
15. Hollister DW, Godfrey M, Saka LY, Pyerity RE. Immunohistologic abnormalities of the microfibrillar-fiber system in the Marfan syndrome. N. Engl. J. Med. 1990; 323:152-159 (Pubitemid 20219943)
16. Hutchinson S, Furger A, Halliday D, et al. Allelic variation in normal human FBN1 expression in a family with Marfan syndrome: a potential modifier of phenotype? Hum. Mol. Genet. 2003; 12:2269-2276
17. Kim SY, Martin N, Hsia EC, Pyeritz RE, Albert DA. Management of aortic disease in Marfan syndrome: a decision analysis. Arch. Intern. Med. 2005; 165:749-755
18. Lacro RV, Dietz HC, Wruck LM, et al. Rationale and design of a randomized clinical trial of B-blocker therapy (atenonol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am. Heart J. 2007; 154:62-131
19. LeParc JM. Bone mineral density in sixty adult patients with Marfan syndrome. Osteoporos. Int. 1999; 10:475-479
20. Lipscomb KJ, Clayton-Smith J, Harris R. Evolving phenotype of Marfan's syndrome. Arch. Dis. Child. 1997; 76:41-46
21. Macura KJ, Szarf G, Fishman EK, Bluemke DA. Role of computed tomography and magnetic resonance imaging in assessment of acute aortic syndromes. Semin. Ultrasound CT MR. 2003; 24:232-254
22. Maron BJ, Ackerman MJ, Nishimura RA, et al. Task Force 4: HCM, other cardiomyopathies, and Marfan. J. Am. Coll. Cardiol. 2005; 45:1340-1345
23. Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation. 2004; 109:2807-2816
24. Matt P, Habashi J, Carrel T, et al. Recent advances in understanding Marfan syndrome: should we now treat surgical patients with losartan? J. Thorac. Cardiovasc. Surg. 2008; 135:389-394
25. Maumenee IH. The eye in the Marfan syndrome. Tr. Am. Ophth. Soc. 1981; LXXIX:684-733.
26. Milewicz DM, Dietz HC, Miller CD. The management of aortic disease in patients with Marfan syndrome. Circulation. 2005; 111:e150-7.
27. Milewicz DM, Grossfield J, Cao S-N, et al. A mutation in FBN1 disrupts profibrillin processing and results in isolated skeletal features of the Marfan syndrome. J. Clin. Invest. 1995; 95:2373-2378
28. Mitchell JH, Haskell WL, Raven PB. Revised eligibility: recommendations for competitive athletes with cardiovascular abnormalities. J. Am. Coll. Cardiol. 1994; 24:864-866
29. Mitchell JH, Haskell W, Snell P, van Camp SP. Task Force 8: classification of sports. J. Am. Coll. Cardiol. 2005; 45:1364-1367
30. Mizuguchi T, Collod-Beroud G, Akiyama T, et al. Heterozygous TGFBRS mutations in Marfan syndrome. Nat. Genet. 2004; 36:855-860
31. Nicod P, Bloor C, Godfrey M, et al. Familial aortic dissecting aneurysms. J. Am. Coll. Cardiol. 1989; 13:811-819
32. Ng CM, Cheng A, Myers LA, et al. TGF-B1-dependent pathogenesis of mitral valve prolapsed in a mouse model of Marfan syndrome. J. Clin. Invest. 2004; 114:1586-1592
33. Nuss D, Kelly RE Jr. Minimally-invasive correction of chest wall deformities. Adv. Pediatr. 2008; 55:395-410.
34. Pyeritz RC. Marfan syndrome and other disorders in fibrillin. In: Rimoin DL, Conner JM and Pyeritz RE, editors. Principles and Practice of Medical Genetics, 3rd ed. Edinburgh: Churchill-Livingstone; 1997, p. 1027-1066
35. Rice SG. Medical conditions affecting sports participation. Pediatrics. 2008; 121:841-848
36. Roman MJ, Devereux RB, Kramer-Fox R, O'Loughlin J. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. Am. J. Cardiol. 1989; 64:507-512
37. Rose PS, Levy HP, Ahn NU, et al. A comparison of the Berlin and Ghent nosologies and the influence of dural ectasia in the diagnosis of Marfan syndrome. Genet. Med. 2000; 2:278-282
38. Savunen T. Cardiovascular abnormalities in relatives of patients operated on for annulo-aortic ectasia: a clinical and echocardiographic study on 40 families. Eur. J. Cardiothorac. Surg. 1987; 1:3-10.
39. Shores J, Berger KR, Murphy E, et al. Progression of aortic dilation and the benefit of long-term beta-andrenergic blockade in Marfan syndrome. N. Engl. J. Med. 1994; 330:1335-1341
40. Silverman DI Burton BS, Gray J, et al. Life expectancy in the Marfan syndrome. Am. J. Cardiol. 1995; 75:157-160
41. Summers KM, West JA, et al. Challenges in the diagnosis of Marfan syndrome. MJA. 2006; 184:627-631
42. Tsipouras P, Del Mastro R, Sarfarzi M, et al. Genetic linkage of the Marfan syndrome, ectopic lentis, and congenital contractual arachnodactyly in the fibrillin genes on chromosomes 15 and 5. N. Engl. J. Med. 1992; 326:905-909
43. Viljoen D. Congenital contractual arachnodactyly (Beals Syndrome). J. Med. Genet. 1994; 31:640-643
44. Williams A, Davies S, Stuart AG, Wilson DG, Fraser AG. Medical treatment for Marfan syndrome: a time for change. Heart. 2008; 94:414-421